Roivant Reports FY26 Revenue Plunge to $8.26M, Widened Net Loss to ($299.77M)
ROIV has more than doubled off its 52-week low of $10.58.
Summary
Roivant Sciences reported its full fiscal year 2026 results, revealing a significant revenue decline of 71.6% year-over-year to $8.26 million and a widened net loss of ($299.77 million), or diluted EPS of ($0.54). This follows earlier news of an unexpected Q4 net profit, which was primarily driven by a $770.2 million litigation settlement gain also detailed in this 10-K summary. While the settlement provides a substantial cash infusion, the full-year operational results indicate a challenging period with declining core revenue and increasing losses, raising questions about the company's underlying business performance. Traders will be evaluating the sustainability of the company's financial position and the progress of its late-stage clinical programs against these significant annual losses.
At the time of this announcement, ROIV was trading at $30.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.2B. The 52-week trading range was $10.58 to $30.33. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.